Oncology News | pharmaphorum

News

Chronic lymphocytic leukemia (CLL) is a type of cancer of the blood and bone marrow - the spongy tissue inside bones where blood cells are made.

TG Therapeutics challenges Roche with FDA filing for CLL dru...

US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic lymphocytic leukaemia, in a challenge to Roche.

News

Roche, Blueprint raise pressure on Lilly with new Gavreto ap...

The FDA has cleared Roche and Blueprint Medicine’s Gavreto for a new use in RET-mutated thyroid cancer, putting it on a level playing field with Eli Lilly’s rival therapy Retevmo.<

News

Genmab axes development of AXL-targeting cancer drug enapota...

Genmab has axed development of its pipeline cancer drug enapotamab vedotin after it failed to show enough activity in a proof-of-concept trial.

News

Y-mAbs claims FDA OK for neuroblastoma drug Danyelza

Y-mAbs Therapeutics has claimed its first product approval, getting a green light from the FDA for Danyelza for the rare cancer neuroblastoma.

News

Catamaran joins the CAR-NK fleet, raising $42m in first roun...

Catamaran Bio has weighed anchor with a $42 million first-round financing that will be used to pull its off-the-shelf natural killer (NK) cell therapies for cancer through early-stage devel

News

FDA sets May date for verdict on ADC’s lymphoma drug Lonca

ADC Therapeutics could claim its first product approval in the US next May, after the FDA started a priority review of lead drug Lonca for diffuse large B-cell lymphoma (DLBCL), an aggressi

TG Therapeutics challenges Roche with FDA filing for CLL dru...

Roche, Blueprint raise pressure on Lilly with new Gavreto ap...

Genmab axes development of AXL-targeting cancer drug enapota...

Y-mAbs claims FDA OK for neuroblastoma drug Danyelza

Catamaran joins the CAR-NK fleet, raising $42m in first roun...

FDA sets May date for verdict on ADC’s lymphoma drug Lonca

GSK to quit Stevenage for new R&D site in Cambridge

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks